China's Yingke Biopharmaceutical bags $42.4m in Series B round

Yingke Biopharmaceutical has raised 300 million yuan ($42.4 million) in a Series B round led by Hong Kong-listed China Life Insurance’s private equity arm as it looks to expand its operations across the country.